Acumen Pharmaceuticals sets investor day and development timeline
Acumen Pharmaceuticals said it will host a live-webcast Investor Day. It also said ALTITUDE-AD topline results are expected in late 2026 and an EBD lead candidate IND is targeted for mid-2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.